GLP medications are drugs that activate the glucagon-like peptide-1 (GLP-1) receptor to lower blood sugar, slow gastric emptying, and reduce appetite. Approved US options include liraglutide, exenatide, dulaglutide, semaglutide (Ozempic, Wegovy, Rybelsus), and tirzepatide (Mounjaro, Zepbound). Tirzepatide also activates the GIP receptor and is often grouped with GLP medications in common usage. These drugs treat type 2 diabetes, chronic weight management, and, for some agents, reduce cardiovascular risk.
Who Counts as a GLP Medication
Strictly speaking, “GLP medications” refers to GLP-1 receptor agonists: drugs that bind the GLP-1 receptor and produce actions similar to the natural hormone. Tirzepatide is a dual GLP-1 and GIP agonist, and is commonly included in the GLP category in news and patient conversations even though its mechanism is broader. There is no currently approved GLP-2 agent used for metabolic disease; teduglutide (Gattex) is a GLP-2 analog used only for short bowel syndrome.
For definitional background on what “GLP” means, our prediabetes 101 hub includes a more basic explainer. Clinical guideline references appear later in this article.
Approved GLP Medications at a Glance
The table below summarizes the major US-approved GLP medications, their approved indications, and typical effects observed in pivotal trials.
| Drug (Brand) | Class | Main Indication | Route | Typical A1C Drop | Typical Weight Loss |
|---|---|---|---|---|---|
| Exenatide (Byetta, Bydureon) | GLP-1 agonist | Type 2 diabetes | Injection twice-daily or weekly | 0.8 to 1.5% | 2 to 4 kg |
| Liraglutide (Victoza, Saxenda) | GLP-1 agonist | Type 2 diabetes; chronic weight management | Injection daily | 1.0 to 1.5% | 5 to 8% body weight |
| Dulaglutide (Trulicity) | GLP-1 agonist | Type 2 diabetes | Injection weekly | 1.2 to 1.7% | 2 to 4 kg |
| Semaglutide (Ozempic) | GLP-1 agonist | Type 2 diabetes; CV risk | Injection weekly | 1.5 to 2.0% | 4 to 6 kg |
| Semaglutide (Wegovy) | GLP-1 agonist | Chronic weight management | Injection weekly | Weight indication | 12 to 15% body weight |
| Semaglutide (Rybelsus) | GLP-1 agonist (oral) | Type 2 diabetes | Oral daily | 1.0 to 1.4% | 3 to 5 kg |
| Tirzepatide (Mounjaro) | GLP-1 + GIP agonist | Type 2 diabetes | Injection weekly | 1.9 to 2.4% | 7 to 11 kg |
| Tirzepatide (Zepbound) | GLP-1 + GIP agonist | Chronic weight management; OSA | Injection weekly | Weight indication | 18 to 22% body weight |
How GLP Medications Work
GLP medications act through several mechanisms that together improve metabolic control.
- Glucose-dependent insulin release. They amplify insulin secretion only when blood sugar is high, lowering hypoglycemia risk compared to insulin itself.
- Glucagon suppression. They reduce liver glucose output between meals.
- Slowed gastric emptying. Food leaves the stomach more slowly, blunting post-meal peaks.
- Appetite reduction. They act on hypothalamic pathways to reduce hunger and increase satiety.
- Cardiovascular benefits. Several agents have shown reductions in major adverse cardiac events in trials.
Benefits Beyond Blood Sugar
Cardiovascular outcome trials have shown meaningful benefits for several GLP medications in people with type 2 diabetes and established heart disease. Liraglutide (LEADER), semaglutide (SUSTAIN-6), and dulaglutide (REWIND) all reduced major cardiovascular events. The SELECT trial of semaglutide 2.4 mg in people with overweight or obesity and cardiovascular disease (without diabetes) showed a 20 percent reduction in cardiovascular events. Wegovy carries an FDA indication to reduce cardiovascular risk in certain adults. According to the FDA, additional indications continue to be reviewed.
Side Effects
Gastrointestinal effects are the most common side effects of GLP medications. Nausea, diarrhea, vomiting, constipation, and reduced appetite occur in 15 to 40 percent of users during dose escalation, and usually improve over weeks to months. Most people who discontinue do so because of persistent GI symptoms rather than safety concerns. Rare but serious risks include pancreatitis, gallbladder disease, and acute kidney injury from dehydration. A boxed warning for thyroid C-cell tumors, based on rodent studies, contraindicates these drugs in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
Who Typically Benefits
GLP medications are generally considered for adults with type 2 diabetes whose glucose targets are not met on lifestyle changes and metformin, particularly those who would benefit from weight loss or have cardiovascular or kidney disease. For chronic weight management, approved criteria typically include BMI 30+ or BMI 27+ with weight-related comorbidity. Insurance coverage varies dramatically by indication and plan. Our treatment hub provides more detailed guidance on fit.
Cost, Access, and Future Pipeline
US list prices for GLP medications range from roughly $1,000 to $1,350 per month, though commercial insurance, manufacturer savings cards, and patient assistance programs can substantially reduce out-of-pocket costs for eligible patients. Several oral non-peptide GLP-1 candidates (including orforglipron) and next-generation dual/triple agonists (including retatrutide) are in late-stage development and could expand the class further over the next several years.
The Bottom Line
GLP medications are the most effective pharmacologic class currently available for type 2 diabetes and obesity, with meaningful cardiovascular and kidney benefits for select patients. Gastrointestinal side effects are common but usually manageable, and serious adverse events are rare. Drug choice depends on the indication, the person’s overall health profile, insurance coverage, and clinician judgment. Discuss options with a prescriber rather than self-selecting a specific brand.
Medical disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider with any questions about a medical condition or treatment.
